Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2016 Jan 15:17:44-6.
doi: 10.1016/j.rmcr.2016.01.004. eCollection 2016.

Immunomodulatory effect of macrolides: At what cost?

Maria Kipourou  1 , Katerina Manika  2 , Apostolos Papavasileiou  3 , Georgia Pitsiou  4 , Martha Lada  2 , Evangelos Ntinapogias  5 , Ioannis Kioumis  2
Affiliations
Case Reports

Immunomodulatory effect of macrolides: At what cost?

Maria Kipourou et al. Respir Med Case Rep. .

Abstract

We present the case of a 60-year old female patient, with a 10 year history of non-CF bronchiectasis and use of macrolides as maintenance immunomodulatory treatment, who was diagnosed with macrolide-resistant Mycobacterium avium complex lung disease. Macrolides' immunomodulatory effect is appealing for non- CF bronchiectasis patients, hiding a high risk for resistance emergence.

Keywords: Bronchiectasis; Macrolides; Non-tuberculous mycobacteria.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Chest CT scan on diagnosis.
Fig. 2
Fig. 2
Chest CT scan after 24 months of treatment.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Griffith D.E., Aksamit T., Brown-Elliott B.A., Catanzaro A., Daley C., Gordin F. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am. J. Respir. Crit. Care Med. 2007;175(4):367–416. - PubMed
    1. Fujita K., Ito Y., Hirai T., Kubo T., Togashi K., Ichiyama S. Prevalence and risk factors for chronic co-infection in pulmonary Mycobacterium avium complex disease. BMJ Open Respir. Res. 2014;1(1):e000050. - PMC - PubMed
    1. Winthrop K.L., McNelley E., Kendall B., Marshall-Olson A., Morris C., Cassidy M. Pulmonary nontuberculous mycobacterial disease prevalence and clinical features: an emerging public health disease. Am. J. Respir. Crit. Care Med. 2010;182(7):977–982. - PubMed
    1. Mirsaeidi M., Hadid W., Ericsoussi B., Rodgers D., Sadikot R.T. Non-tuberculous mycobacterial disease is common in patients with non-cystic fibrosis bronchiectasis. Int. J. Infect. Dis. 2013;17(11):e1000–e1004. - PMC - PubMed
    1. Maiga M., Siddiqui S., Diallo S., Diarra B., Traoré B., Shea Y.R. Failure to recognize nontuberculous mycobacteria leads to misdiagnosis of chronic pulmonary tuberculosis. PloS one. 2012;7(5):e36902. - PMC - PubMed

Publication types

LinkOut - more resources